Reports indicate the positive therapeutic potential of ACE2 supplementation in COVID-19 patients. Others have suggested that the Nsp-1 (non-structural protein 1) of COVID-19 has high virulence. Removing Nsp-1 from the viral genome and developing a vaccine with milder disease might be promising. What other trends have we observed in innate immunity?